These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 10051051)
1. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group. Marsh CL Ther Drug Monit; 1999 Feb; 21(1):27-34. PubMed ID: 10051051 [TBL] [Abstract][Full Text] [Related]
2. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R Pediatr Transplant; 1999 Nov; 3(4):282-7. PubMed ID: 10562972 [TBL] [Abstract][Full Text] [Related]
3. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group. Pollak R; Wong RL; Chang CT Ther Drug Monit; 1999 Dec; 21(6):661-3. PubMed ID: 10604829 [TBL] [Abstract][Full Text] [Related]
4. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050 [TBL] [Abstract][Full Text] [Related]
5. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Grant D; Kneteman N; Tchervenkov J; Roy A; Murphy G; Tan A; Hendricks L; Guilbault N; Levy G Transplantation; 1999 Apr; 67(8):1133-7. PubMed ID: 10232563 [TBL] [Abstract][Full Text] [Related]
6. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation. Meier-Kriesche HU; Kaplan B; Brannan P; Kahan BD; Portman RJ Ther Drug Monit; 1998 Aug; 20(4):401-7. PubMed ID: 9712465 [TBL] [Abstract][Full Text] [Related]
7. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
8. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related]
9. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related]
10. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. International Neoral Renal Transplantation Study Group. Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen. Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS Transplant Proc; 2006 Sep; 38(7):2132-4. PubMed ID: 16980022 [TBL] [Abstract][Full Text] [Related]
12. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral. Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433 [TBL] [Abstract][Full Text] [Related]
13. Improving the therapeutic monitoring of cyclosporin A. Warrens AN; Waters JB; Salama AD; Lechler RI Clin Transplant; 1999 Apr; 13(2):193-200. PubMed ID: 10202617 [TBL] [Abstract][Full Text] [Related]
14. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Mahalati K; Belitsky P; Sketris I; West K; Panek R Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. White M; Pelletier GB; Tan A; Jesina C; Carrier M J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770 [TBL] [Abstract][Full Text] [Related]
16. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation. Alvarez F; Atkison PR; Grant DR; Guilbault N; Jones AB; Kim PS; Kneteman NM; Laurin L; Martin SR; Murphy GF; Paradis K; Shapiro J; Smith LJ; Superina RA Transplantation; 2000 Jan; 69(1):87-92. PubMed ID: 10653385 [TBL] [Abstract][Full Text] [Related]
20. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. Gaspari F; Anedda MF; Signorini O; Remuzzi G; Perico N J Am Soc Nephrol; 1997 Apr; 8(4):647-52. PubMed ID: 10495795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]